Haemophilus b conjugate vaccine (tetanus toxoid conjugate, GlaxoSmithKline)

N/A

Report date: 2022/08/29 20:00:24

Base Information

Drug NameHaemophilus b conjugate vaccine (tetanus toxoid conjugate, GlaxoSmithKline)
Drug Alias NameB型嗜血杆菌结合疫苗（破伤风类毒素结合物，葛兰素史克）Hiberix
ClassificationVaccines > Biological material > Bacterial vaccineVaccines > Biological material > Toxoid vaccineVaccines > Application > Prophylactic vaccine +[4] 
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsHepatitis BMalariaPoliomyelitis +[9] 
Global Approved IndicationsHaemophilus Infections
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2009/08/19
Country/TerritoryUnited StatesPolandThailand +[11] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPending
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsHaemophilus Infections
Inactive IndicationsHepatitis BMalariaPoliomyelitis +[8] 

Other Information

ATC CodeJ07AG51
Related LinksN/A